NASDAQ:SPRB Spruce Biosciences (SPRB) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free SPRB Stock Alerts $0.70 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.70▼$0.7150-Day Range$0.69▼$5.4952-Week Range$0.67▼$5.95Volume211,577 shsAverage Volume675,708 shsMarket Capitalization$28.81 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Spruce Biosciences alerts: Email Address Spruce Biosciences MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside709.5% Upside$5.67 Price TargetShort InterestHealthy0.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 3 Articles This WeekInsider TradingSelling Shares$2.61 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.33) to ($1.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.89 out of 5 starsMedical Sector209th out of 913 stocksPharmaceutical Preparations Industry84th out of 425 stocks 4.1 Analyst's Opinion Consensus RatingSpruce Biosciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageSpruce Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.74% of the float of Spruce Biosciences has been sold short.Short Interest Ratio / Days to CoverSpruce Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spruce Biosciences has recently decreased by 48.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpruce Biosciences does not currently pay a dividend.Dividend GrowthSpruce Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SPRB. Previous Next 1.9 News and Social Media Coverage News SentimentSpruce Biosciences has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Spruce Biosciences this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for SPRB on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Spruce Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spruce Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,613,101.00 in company stock.Percentage Held by InsidersOnly 9.10% of the stock of Spruce Biosciences is held by insiders.Percentage Held by Institutions91.71% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Spruce Biosciences are expected to grow in the coming year, from ($1.33) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spruce Biosciences is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spruce Biosciences is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpruce Biosciences has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market Insiders4 coins to be the “Next Bitcoin”The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Spruce Biosciences Stock (NASDAQ:SPRB)Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Read More SPRB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRB Stock News HeadlinesApril 26, 2024 | investing.comSpruce Biosciences Inc (SPRB)April 22, 2024 | businesswire.comSpruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual MeetingApril 28, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 20, 2024 | americanbankingnews.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Rating of "Hold" by AnalystsApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBMarch 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBMarch 23, 2024 | finance.yahoo.comRevenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)March 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBApril 28, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 16, 2024 | finance.yahoo.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target PriceMarch 14, 2024 | marketwatch.comSpruce Biosciences Shares Dive 74% After Terminating Genetic Disease Study, Cutting StaffMarch 14, 2024 | markets.businessinsider.comSpruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock FreefallMarch 14, 2024 | businesswire.comSpruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 14, 2024 | marketwatch.comStocks to Watch: Spruce Biosciences, UiPathMarch 14, 2024 | markets.businessinsider.comSpruce Biosciences FY23 Loss Widens, CAHmelia-203 Study Fails; Stock Down In Pre-marketMarch 14, 2024 | msn.comWhy Is Rare Endocrine Disorder-Focused Spruce Biosciences Stock Plummeting On Thursday?March 14, 2024 | investorplace.comWhy Is Spruce Biosciences (SPRB) Stock Down 78% Today?March 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Spruce Biosciences Amid Clinical Trial Optimism and Advancing Dose CohortsMarch 13, 2024 | msn.comSpruce Biosciences stock craters 75% on failed Phase 2 studyMarch 13, 2024 | finance.yahoo.comSpruce Biosciences Inc (SPRB) Reports Full Year 2023 Financial Results Amid Clinical Trial SetbacksMarch 13, 2024 | businesswire.comSpruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate UpdatesMarch 13, 2024 | businesswire.comSpruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAHFebruary 23, 2024 | benzinga.comSpruce Biosciences Stock (NASDAQ:SPRB), Short Interest ReportFebruary 21, 2024 | msn.comGuggenheim starts Spruce Biosciences at buy, cites near-term catalystsFebruary 21, 2024 | msn.comGuggenheim Initiates Coverage of Spruce Biosciences (SPRB) with Buy RecommendationJanuary 30, 2024 | finance.yahoo.comSpruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 22, 2024 | finance.yahoo.comSpruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal HyperplasiaSee More Headlines Receive SPRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SPRB CUSIPN/A CIK1683553 Webwww.sprucebiosciences.com Phone415-655-4168FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Target$5.67 High Stock Price Target$10.00 Low Stock Price Target$2.00 Potential Upside/Downside+709.5%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,920,000.00 Net Margins-474.96% Pretax Margin-474.96% Return on Equity-52.31% Return on Assets-39.77% Debt Debt-to-Equity Ratio0.02 Current Ratio4.18 Quick Ratio4.18 Sales & Book Value Annual Sales$10.09 million Price / Sales2.85 Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book0.37Miscellaneous Outstanding Shares41,150,000Free Float37,408,000Market Cap$28.81 million OptionableOptionable Beta2.52 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Michael G. Grey (Age 71)Executive Chairman Comp: $70kDr. Javier Szwarcberg M.D. (Age 54)M.P.H., CEO & Director Comp: $951.85kMr. Samir M. Gharib CPA (Age 42)M.B.A., President & CFO Comp: $683.63kDr. Ralph William Charlton III (Age 54)M.D., Chief Medical Officer Comp: $647.4kMs. P. J. RamtinSenior Vice President of Business OperationsMs. Heidi Petersen M.P.H.Senior Vice President of Regulatory & QualityMore ExecutivesKey CompetitorsLexaria BioscienceNASDAQ:LEXXAprea TherapeuticsNASDAQ:APREDaré BioscienceNASDAQ:DARENRx PharmaceuticalsNASDAQ:NRXPAcasti PharmaNASDAQ:ACSTView All CompetitorsInsiders & InstitutionsRosalind Advisors Inc.Sold 77,973 shares on 4/25/2024Ownership: 3.666%Holdings A/S NovoSold 359,979 sharesTotal: $262,784.67 ($0.73/share)Holdings A/S NovoSold 842,020 sharesTotal: $648,355.40 ($0.77/share)Holdings A/S NovoSold 1,912,316 sharesTotal: $1.70 M ($0.89/share)Superstring Capital Management LPBought 118,814 shares on 2/14/2024Ownership: 0.292%View All Insider TransactionsView All Institutional Transactions SPRB Stock Analysis - Frequently Asked Questions Should I buy or sell Spruce Biosciences stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SPRB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRB, but not buy additional shares or sell existing shares. View SPRB analyst ratings or view top-rated stocks. What is Spruce Biosciences' stock price target for 2024? 8 brokerages have issued 12-month target prices for Spruce Biosciences' stock. Their SPRB share price targets range from $2.00 to $10.00. On average, they predict the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 709.5% from the stock's current price. View analysts price targets for SPRB or view top-rated stocks among Wall Street analysts. How have SPRB shares performed in 2024? Spruce Biosciences' stock was trading at $2.93 on January 1st, 2024. Since then, SPRB shares have decreased by 76.1% and is now trading at $0.70. View the best growth stocks for 2024 here. Are investors shorting Spruce Biosciences? Spruce Biosciences saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 164,000 shares, a drop of 48.8% from the March 31st total of 320,400 shares. Based on an average daily volume of 1,320,000 shares, the short-interest ratio is presently 0.1 days. Approximately 0.7% of the shares of the stock are sold short. View Spruce Biosciences' Short Interest. When is Spruce Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SPRB earnings forecast. How were Spruce Biosciences' earnings last quarter? Spruce Biosciences, Inc. (NASDAQ:SPRB) announced its earnings results on Wednesday, March, 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.18. The company earned $2.89 million during the quarter, compared to analyst estimates of $1.65 million. Spruce Biosciences had a negative net margin of 474.96% and a negative trailing twelve-month return on equity of 52.31%. When did Spruce Biosciences IPO? Spruce Biosciences (SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO. Who are Spruce Biosciences' major shareholders? Spruce Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rosalind Advisors Inc. (3.67%). Insiders that own company stock include Camilla V Simpson and Holdings A/S Novo. View institutional ownership trends. How do I buy shares of Spruce Biosciences? Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SPRB) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
